Ligand Pharmaceuticals Incorporated
LGND
NSD
Sector: Healthcare
Industry: Biotechnology
97.13
USD
-0.40
(-0.41%)
Optionable: Yes Market Cap: 1,555 M 90-day average vol: 0
Previous close: 97.53 Open: 96.36 Bid: 110.45 Ask: 110.45
52 week range
0.00 0.00
Last updated: Monday 8th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 8.50 |
Price per Book TTM ($) | 1.91 |
PE Ratio (TTM) | 66.40 |
Book Value per Share ($) | 47.04 |
5 Year PE Range-544.7 |
Returns
7 Day Return | 8.28% | |
1 Month Return | 2.24% | |
3 Month Return | 19.56% | |
1 Year Return | -11.64% | |
3 Year Return | 3.46% | |
5 Year Return | -24.69% | |
YTD Return | -37.12% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 58.92 |
14 Day SMA ($) | 93.75 |
14 Day EMA ($) | 93.93 |
Money Flow Index | 60.44 |
Average True Range | 3.79 |
50 Day SMA ($) | 88.82 |
200 Day SMA ($) | 114.97 |
ADX | 38.89 |
MACD | 1.50 |
Growth
Free Cash Flow QoQ Growth | 85.23% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 203.33% |
Revenue QoQ Growth | -36.95% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Investors one-year losses grow to 37% as the stock sheds US$288m this past week
Yahoo Finance 2/24/2022
Ligand (LGND) Q4 Earnings Beat, OmniAb Spin-Off in 1H22
Yahoo Finance 2/18/2022
Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha 2/17/2022
Ligand Pharmaceuticals Non-GAAP EPS of $1.80 beats by $0.43, revenue of $72.5M beats by $7.41M
Seeking Alpha 2/17/2022
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
Yahoo Finance 2/17/2022
Ligand Pharmaceuticals Q4 2021 Earnings Preview
Seeking Alpha 2/16/2022
Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More
Yahoo Finance 2/16/2022
Ligand to Report Fourth Quarter Financial Results on February 17
Yahoo Finance 2/9/2022
Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA
Yahoo Finance 1/26/2022
Absci (ABSI) Inks Research Agreement With Merck, Stock Up
Yahoo Finance 1/10/2022
Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year
Seeking Alpha 12/31/2021
Syntax Etf Trust Buys Perrigo Co PLC, Unum Group, GameStop Corp, Sells Ligand Pharmaceuticals ...
Yahoo Finance 12/28/2021
Advisors' Inner Circle Fund III Buys Washington Federal Inc, Supernus Pharmaceuticals Inc, ...
Yahoo Finance 12/28/2021
DeltaShares(R) S&P 600 Managed Risk ETF Buys Ligand Pharmaceuticals Inc, Apollo Medical ...
Yahoo Finance 12/28/2021
Ligand (LGND) Stock Surges 60% YTD: What's Driving the Rally?
Yahoo Finance 12/27/2021
Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 27% Discount?
Yahoo Finance 12/26/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 15.63
Financials
LGND Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 31 M | 49 M | 65 M | 72 M | 109 M | 141 M | 251 M | 120 M | 186 M | 277 M |
| Cost of sales | 874000 | 3 M | 6 M | 3 M | -7 M | -6 M | -2 M | -22 M | -4 M | 7 M |
| Gross operating profit | 28 M | 43 M | 56 M | 66 M | 104 M | 135 M | 244 M | 109 M | 161 M | 219 M |
| Selling Gen & administrative expense | 16 M | 18 M | 23 M | 25 M | 28 M | 29 M | 38 M | 42 M | 64 M | 20 M |
| Research & development expense | 11 M | 9 M | 10 M | 11 M | 21 M | 27 M | 28 M | 56 M | 59 M | 69 M |
| Operating income | 1 M | 16 M | 21 M | 27 M | 44 M | 68 M | 164 M | -6 M | 9 M | 79 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -2 M | -5 M | -5 M | 20 M | -24 M | 555000 | 44 M | 810 M | 73000 | -13 M |
| Pre-tax Income (EBT) | -4 M | 9 M | 11 M | 35 M | 8 M | 57 M | 173 M | 797 M | -11 M | 47 M |
| Income taxes | -1 M | 374000 | 410000 | -192 M | 10 M | 45 M | 30 M | 167 M | -8 M | -10 M |
| Net income from total operations | -527000 | 11 M | 11 M | 227 M | -2 M | 13 M | 143 M | 629 M | -3 M | 57 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -527000 | 11 M | 12 M | 230 M | -2 M | 13 M | 143 M | 629 M | -3 M | 57 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -3 M | 9 M | 11 M | 227 M | -2 M | 13 M | 143 M | 629 M | -3 M | 57 M |
| Depreciation | 3 M | 3 M | 3 M | 3 M | 12 M | 12 M | 9 M | 33 M | 29 M | 51 M |
| Amortization | 0 | 0 | 2 M | 2 M | 11 M | 12 M | 16 M | 17 M | 23 M | 47 M |
| Operating income before depreciation (EBITDA) | 4 M | 19 M | 23 M | 30 M | 32 M | 83 M | 237 M | 876 M | 45 M | 118 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -0.03 | 0.56 | 0.59 | 13 | -0.08 | 0.6 | 6.77 | 33.13 | -0.18 | 3.44 |
| Diluted EPS total | -0.03 | 0.55 | 0.56 | 12.12 | -0.08 | 0.53 | 5.96 | 31.85 | -0.18 | 3.31 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!